Sandbox Reserved 1227
From Proteopedia
(Difference between revisions)
Line 4: | Line 4: | ||
== Function == | == Function == | ||
- | Mdm2 is an E3 ubiquitin ligase that ubiquitylates and | + | Mdm2 is an E3 ubiquitin ligase that ubiquitylates and binds the transcriptional activation domain of p53 to signal degradation of the cell. MDM2 and the closely related MDM4 are two of the main inhibitory proteins of the p53 pathway. The p53 pathway is activated when the cell is distressed and needs to be broken down. The p53 pathway leads to the ceasing of proliferation of the cell, or cell death. The expression of MDMD2 is activated by p53 by an auto regulatory feedback loop<ref>Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997). Mdm2 promotes the rapid degradation of p53. Nature, 387(6630), 296-9. doi:http://dx.doi.org/10.1038/387296a0</ref>. Too much MDM2 can turn off the p53 pathway, allowing the cell to grow uncontrollably, allowing for tumor growth. The association between p53 and the MDM proteins can be seen in <scene name='75/750276/Mdm4-p53_interaction/1'>p53-MDM4 interaction</scene>. On the other hand, if MDM2 or MDM4 is under regulated, p53 will overwork, causing cell death more often and earlier on than necessary.<ref>Eischen, C. M., & Lozano, G. (2014). The Mdm network and its regulation of p53 activities: a rheostat of cancer risk. Human Mutation, 35(6), 728–737. http://doi.org/10.1002/humu.22524</ref> |
== Relevance == | == Relevance == |
Revision as of 02:23, 27 April 2017
This Sandbox is Reserved from Jan 17 through June 31, 2017 for use in the course Biochemistry II taught by Jason Telford at the Maryville University, St. Louis, USA. This reservation includes Sandbox Reserved 1225 through Sandbox Reserved 1244. |
To get started:
More help: Help:Editing |
MDM2
|
References
- ↑ Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997). Mdm2 promotes the rapid degradation of p53. Nature, 387(6630), 296-9. doi:http://dx.doi.org/10.1038/387296a0
- ↑ Eischen, C. M., & Lozano, G. (2014). The Mdm network and its regulation of p53 activities: a rheostat of cancer risk. Human Mutation, 35(6), 728–737. http://doi.org/10.1002/humu.22524
- ↑ Wang, P., Wang, M., Li, S., Ma, L., Xi, S., & He, J. (2016). Association of the MDM2 SNP285 Polymorphism with Cancer Susceptibility: A Meta-Analysis. Disease Markers, 20164585484.
- ↑ Trino, S., De Luca, L., Laurenzana, I., Caivano, A., Del Vecchio, L., Martinelli, G., & Musto, P. (2016). P53-MDM2 Pathway: Evidences for A New Targeted Therapeutic Approach in B-Acute Lymphoblastic Leukemia. Frontiers in Pharmacology, 7, 491. http://doi.org/10.3389/fphar.2016.00491.
- ↑ Ciemny, M. P., Debinski, A., Paczkowska, M., Kolinski, A., Kurcinski, M., & Kmiecik, S. (2016). Protein-peptide molecular docking with large-scale conformational changes: the p53-MDM2 interaction. Scientific Reports, 6, 37532. http://doi.org/10.1038/srep37532.